Skip to main content
Top
Published in: Journal of Gastroenterology 1/2007

Open Access 01-01-2007 | Review

Inflammatory bowel disease: past, present, and future

Author: Bruce E. Sands

Published in: Journal of Gastroenterology | Issue 1/2007

Login to get access

Abstract

Crohn’s disease and ulcerative colitis, collectively known as the inflammatory bowel diseases (IBD), are largely diseases of the twentieth century, and are associated with the rise of modern, Westernized industrial society. Although the causes of these diseases remain incompletely understood, the prevailing model is that the intestinal flora drives an unmitigated intestinal immune response and inflammation in the genetically susceptible host. A review of the past and present of these diseases shows that detailed description preceded more fundamental elucidation of the disease processes. Working out the details of disease pathogenesis, in turn, has yielded dividends in more focused and effective therapy for IBD. This article highlights the key descriptions of the past, and the pivotal findings of current studies in disease pathogenesis and its connection to medical therapy. Future directions in the IBD will likely explicate the inhomogeneous causes of these diseases, with implications for individualized therapy.
Literature
1.
go back to reference Kirsner, JB 2001Historical origins of current IBD conceptsWorld J Gastroenterol717584PubMed Kirsner, JB 2001Historical origins of current IBD conceptsWorld J Gastroenterol717584PubMed
2.
go back to reference Crohn, BB, Ginzburg, L, Oppenheimer, GD 2000Regional ileitis: a pathologic and clinical entity. 1932Mt Sinai J Med672638PubMed Crohn, BB, Ginzburg, L, Oppenheimer, GD 2000Regional ileitis: a pathologic and clinical entity. 1932Mt Sinai J Med672638PubMed
3.
go back to reference Lockhart-Mummery, HE, Morson, BC 1960Crohn’s disease (regional enteritis) of the large intestine and its distinction from ulcerative colitisGut187105CrossRefPubMed Lockhart-Mummery, HE, Morson, BC 1960Crohn’s disease (regional enteritis) of the large intestine and its distinction from ulcerative colitisGut187105CrossRefPubMed
4.
go back to reference Azad Khan, AK, Piris, J, Truelove, SC 1977An experiment to determine the active therapeutic moiety of sulphasalazineLancet28925CrossRefPubMed Azad Khan, AK, Piris, J, Truelove, SC 1977An experiment to determine the active therapeutic moiety of sulphasalazineLancet28925CrossRefPubMed
5.
go back to reference Peppercorn, MA, Goldman, P 1972The role of intestinal bacteria in the metabolism of salicylazosulfapyridineJ Pharmacol Exp Ther18155562PubMed Peppercorn, MA, Goldman, P 1972The role of intestinal bacteria in the metabolism of salicylazosulfapyridineJ Pharmacol Exp Ther18155562PubMed
6.
go back to reference Kaplan, HP, Portnoy, B, Binder, HJ, Amatruda, T, Spiro, H 1975A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitisGastroenterology69915PubMed Kaplan, HP, Portnoy, B, Binder, HJ, Amatruda, T, Spiro, H 1975A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitisGastroenterology69915PubMed
7.
go back to reference Truelove, SC, Jewell, DP 1974Intensive intravenous regimen for severe attacks of ulcerative colitisLancet1106770CrossRefPubMed Truelove, SC, Jewell, DP 1974Intensive intravenous regimen for severe attacks of ulcerative colitisLancet1106770CrossRefPubMed
8.
go back to reference Truelove, SC, Witts, LJ 1955Cortisone in ulcerative colitis; final report on a therapeutic trialBMJ494710418CrossRef Truelove, SC, Witts, LJ 1955Cortisone in ulcerative colitis; final report on a therapeutic trialBMJ494710418CrossRef
9.
go back to reference Munkholm, P, Langholz, E, Davidsen, M, Binder, V 1994Frequency of glucocorticoid resistance and dependency in Crohn’s diseaseGut353602CrossRefPubMed Munkholm, P, Langholz, E, Davidsen, M, Binder, V 1994Frequency of glucocorticoid resistance and dependency in Crohn’s diseaseGut353602CrossRefPubMed
10.
go back to reference Present, DH, Korelitz, BI, Wisch, N, Glass, JL, Sachar, DB, Pasternack, BS 1980Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind studyN Engl J Med3029817PubMedCrossRef Present, DH, Korelitz, BI, Wisch, N, Glass, JL, Sachar, DB, Pasternack, BS 1980Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind studyN Engl J Med3029817PubMedCrossRef
11.
go back to reference Korelitz, BI, Present, DH 1985Favorable effect of 6-mercaptopurine on fistulae of Crohn’s diseaseDig Dis Sci305864CrossRefPubMed Korelitz, BI, Present, DH 1985Favorable effect of 6-mercaptopurine on fistulae of Crohn’s diseaseDig Dis Sci305864CrossRefPubMed
12.
go back to reference Ardizzone, S, Maconi, G, Russo, A, Imbesi, V, Colombo, E, Bianchi Porro, G 2006Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitisGut554753CrossRefPubMed Ardizzone, S, Maconi, G, Russo, A, Imbesi, V, Colombo, E, Bianchi Porro, G 2006Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitisGut554753CrossRefPubMed
13.
go back to reference Feagan, BG, Rochon, J, Fedorak, RN, Irvine, EJ, Wild, G, Sutherland, L, et al. 1995Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group InvestigatorsN Engl J Med3322927CrossRefPubMed Feagan, BG, Rochon, J, Fedorak, RN, Irvine, EJ, Wild, G, Sutherland, L,  et al. 1995Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group InvestigatorsN Engl J Med3322927CrossRefPubMed
14.
go back to reference Feagan, BG, Fedorak, RN, Irvine, EJ, Wild, G, Sutherland, L, Steinhart, AH, et al. 2000A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group InvestigatorsN Engl J Med342162732CrossRefPubMed Feagan, BG, Fedorak, RN, Irvine, EJ, Wild, G, Sutherland, L, Steinhart, AH,  et al. 2000A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group InvestigatorsN Engl J Med342162732CrossRefPubMed
15.
go back to reference Lichtiger, S, Present, DH, Kornbluth, A, Gelernt, I, Bauer, J, Galler, G, et al. 1994Cyclosporine in severe ulcerative colitis refractory to steroid therapyN Engl J Med33018415CrossRefPubMed Lichtiger, S, Present, DH, Kornbluth, A, Gelernt, I, Bauer, J, Galler, G,  et al. 1994Cyclosporine in severe ulcerative colitis refractory to steroid therapyN Engl J Med33018415CrossRefPubMed
16.
go back to reference Arts, J, D’Haens, G, Zeegers, M, Van Assche, G, Hiele, M, D’Hoore, A, et al. 2004Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitisInflamm Bowel Dis10738CrossRefPubMed Arts, J, D’Haens, G, Zeegers, M, Van Assche, G, Hiele, M, D’Hoore, A,  et al. 2004Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitisInflamm Bowel Dis10738CrossRefPubMed
17.
go back to reference Fazio, VW, Marchetti, F, Church, M, Goldblum, JR, Lavery, C, Hull, TL, et al. 1996Effect of resection margins on the recurrence of Crohn’s disease in the small bowel. A randomized controlled trialAnn Surg22456371discussion 571–3CrossRefPubMed Fazio, VW, Marchetti, F, Church, M, Goldblum, JR, Lavery, C, Hull, TL,  et al. 1996Effect of resection margins on the recurrence of Crohn’s disease in the small bowel. A randomized controlled trialAnn Surg22456371discussion 571–3CrossRefPubMed
18.
go back to reference Deutsch, AA, Stern, HS 1989Stapler stricturoplasty for Crohn’s diseaseSurg Gynecol Obstet16945860PubMed Deutsch, AA, Stern, HS 1989Stapler stricturoplasty for Crohn’s diseaseSurg Gynecol Obstet16945860PubMed
19.
go back to reference Taylor, BM, Beart, RW,Jr, Dozois, RR, Kelly, KA, Phillips, SF 1983Straight ileoanal anastomosis v ileal pouch–anal anastomosis after colectomy and mucosal proctectomyArch Surg118696701PubMed Taylor, BM, Beart, RW,Jr, Dozois, RR, Kelly, KA, Phillips, SF 1983Straight ileoanal anastomosis v ileal pouch–anal anastomosis after colectomy and mucosal proctectomyArch Surg118696701PubMed
20.
go back to reference Yang, H, McElree, C, Roth, MP, Shanahan, F, Targan, SR, Rotter, JI 1993Familial empirical risks for inflammatory bowel disease: differences between Jews and non-JewsGut3451724CrossRefPubMed Yang, H, McElree, C, Roth, MP, Shanahan, F, Targan, SR, Rotter, JI 1993Familial empirical risks for inflammatory bowel disease: differences between Jews and non-JewsGut3451724CrossRefPubMed
21.
go back to reference Tysk, C, Lindberg, E, Jarnerot, G, Floderus-Myrhed, B 1988Ulcerative colitis and Crohn’s disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smokingGut299906CrossRefPubMed Tysk, C, Lindberg, E, Jarnerot, G, Floderus-Myrhed, B 1988Ulcerative colitis and Crohn’s disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smokingGut299906CrossRefPubMed
23.
go back to reference Hermon-Taylor, J, Bull, T 2002Crohn’s disease caused by Mycobacterium avium subspecies paratuberculosis: a public health tragedy whose resolution is long overdueJ Med Microbiol5136PubMed Hermon-Taylor, J, Bull, T 2002Crohn’s disease caused by Mycobacterium avium subspecies paratuberculosis: a public health tragedy whose resolution is long overdueJ Med Microbiol5136PubMed
24.
go back to reference Odes, HS, Fich, A, Reif, S, Halak, A, Lavy, A, Keter, D, et al. 2001Effects of current cigarette smoking on clinical course of Crohn’s disease and ulcerative colitisDig Dis Sci46171721CrossRefPubMed Odes, HS, Fich, A, Reif, S, Halak, A, Lavy, A, Keter, D,  et al. 2001Effects of current cigarette smoking on clinical course of Crohn’s disease and ulcerative colitisDig Dis Sci46171721CrossRefPubMed
25.
go back to reference Bjarnason, I, Zanelli, G, Smith, T, Prouse, P, Williams, P, Smethurst, P, et al. 1987Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humansGastroenterology934809PubMed Bjarnason, I, Zanelli, G, Smith, T, Prouse, P, Williams, P, Smethurst, P,  et al. 1987Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humansGastroenterology934809PubMed
26.
go back to reference Frisch, M, Johansen, C, Mellemkjaer, L, Engels, EA, Gridley, G, Biggar, RJ, et al. 2001Appendectomy and subsequent risk of inflammatory bowel diseasesSurgery1303643CrossRefPubMed Frisch, M, Johansen, C, Mellemkjaer, L, Engels, EA, Gridley, G, Biggar, RJ,  et al. 2001Appendectomy and subsequent risk of inflammatory bowel diseasesSurgery1303643CrossRefPubMed
27.
go back to reference Cosnes, J, Beaugerie, L, Carbonnel, F, Gendre, JP 2001Smoking cessation and the course of Crohn’s disease: an intervention studyGastroenterology12010939CrossRefPubMed Cosnes, J, Beaugerie, L, Carbonnel, F, Gendre, JP 2001Smoking cessation and the course of Crohn’s disease: an intervention studyGastroenterology12010939CrossRefPubMed
28.
go back to reference Boyko, EJ, Perera, DR, Koepsell, TD, Keane, EM, Inui, TS 1988Effects of cigarette smoking on the clinical course of ulcerative colitisScand J Gastroenterol23114752CrossRefPubMed Boyko, EJ, Perera, DR, Koepsell, TD, Keane, EM, Inui, TS 1988Effects of cigarette smoking on the clinical course of ulcerative colitisScand J Gastroenterol23114752CrossRefPubMed
29.
go back to reference Harries, AD, Baird, A, Rhodes, J 1982Non-smoking: a feature of ulcerative colitisBMJ Clin Res Ed284706CrossRef Harries, AD, Baird, A, Rhodes, J 1982Non-smoking: a feature of ulcerative colitisBMJ Clin Res Ed284706CrossRef
30.
go back to reference Motley, RJ, Rhodes, J, Ford, GA, Wilkinson, SP, Chesner, IM, Asquith, P, et al. 1987Time relationships between cessation of smoking and onset of ulcerative colitisDigestion371257CrossRefPubMed Motley, RJ, Rhodes, J, Ford, GA, Wilkinson, SP, Chesner, IM, Asquith, P,  et al. 1987Time relationships between cessation of smoking and onset of ulcerative colitisDigestion371257CrossRefPubMed
31.
go back to reference McGrath J, McDonald JW, Macdonald JK. Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2004 Oct 18;(4):CD004722 McGrath J, McDonald JW, Macdonald JK. Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2004 Oct 18;(4):CD004722
32.
go back to reference Hegazi, RA, Rao, KN, Mayle, A, Sepulveda, AR, Otterbein, LE, Plevy, SE 2005Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathwayJ Exp Med202170313CrossRefPubMed Hegazi, RA, Rao, KN, Mayle, A, Sepulveda, AR, Otterbein, LE, Plevy, SE 2005Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathwayJ Exp Med202170313CrossRefPubMed
33.
go back to reference Dejaco, C, Harrer, M, Waldhoer, T, Miehsler, W, Vogelsang, H, Reinisch, W 2003Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s diseaseAliment Pharmacol Ther18111320CrossRefPubMed Dejaco, C, Harrer, M, Waldhoer, T, Miehsler, W, Vogelsang, H, Reinisch, W 2003Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s diseaseAliment Pharmacol Ther18111320CrossRefPubMed
34.
go back to reference Wild, GE 2004The role of antibiotics in the management of Crohn’s diseaseInflamm Bowel Dis103213CrossRefPubMed Wild, GE 2004The role of antibiotics in the management of Crohn’s diseaseInflamm Bowel Dis103213CrossRefPubMed
35.
go back to reference Rutgeerts, P, Hiele, M, Geboes, K, Peeters, M, Penninckx, F, Aerts, R, et al. 1995Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resectionGastroenterology108161721CrossRefPubMed Rutgeerts, P, Hiele, M, Geboes, K, Peeters, M, Penninckx, F, Aerts, R,  et al. 1995Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resectionGastroenterology108161721CrossRefPubMed
36.
go back to reference Rutgeerts, P, Van Assche, G, Vermeire, S, D’Haens, G, Baert, F, Noman, M, et al. 2005Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trialGastroenterology12885661CrossRefPubMed Rutgeerts, P, Van Assche, G, Vermeire, S, D’Haens, G, Baert, F, Noman, M,  et al. 2005Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trialGastroenterology12885661CrossRefPubMed
37.
go back to reference Rutgeerts, P, Goboes, K, Peeters, M, Hiele, M, Penninckx, F, Aerts, R, et al. 1991Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileumLancet3387714CrossRefPubMed Rutgeerts, P, Goboes, K, Peeters, M, Hiele, M, Penninckx, F, Aerts, R,  et al. 1991Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileumLancet3387714CrossRefPubMed
38.
go back to reference Yamamoto, T, Nakahigashi, M, Umegae, S, Kitagawa, T, Matsumoto, K 2005Impact of elemental diet on mucosal inflammation in patients with active Crohn’s disease: cytokine production and endoscopic and histological findingsInflamm Bowel Dis115808CrossRefPubMed Yamamoto, T, Nakahigashi, M, Umegae, S, Kitagawa, T, Matsumoto, K 2005Impact of elemental diet on mucosal inflammation in patients with active Crohn’s disease: cytokine production and endoscopic and histological findingsInflamm Bowel Dis115808CrossRefPubMed
39.
go back to reference Gionchetti, P, Rizzello, F, Helwig, U, Venturi, A, Lammers, KM, Brigidi, P, et al. 2003Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial [see commentGastroenterology12412029CrossRefPubMed Gionchetti, P, Rizzello, F, Helwig, U, Venturi, A, Lammers, KM, Brigidi, P,  et al. 2003Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial [see commentGastroenterology12412029CrossRefPubMed
40.
go back to reference Gionchetti, P, Rizzello, F, Venturi, A, Brigidi, P, Matteuzzi, D, Bazzocchi, G, et al. 2000Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trialGastroenterology1193059CrossRefPubMed Gionchetti, P, Rizzello, F, Venturi, A, Brigidi, P, Matteuzzi, D, Bazzocchi, G,  et al. 2000Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trialGastroenterology1193059CrossRefPubMed
41.
go back to reference Fedorak, RN, Madsen, KL 2004Probiotics and the management of inflammatory bowel diseaseInflamm Bowel Dis1028699CrossRefPubMed Fedorak, RN, Madsen, KL 2004Probiotics and the management of inflammatory bowel diseaseInflamm Bowel Dis1028699CrossRefPubMed
42.
go back to reference Rioux, KP, Fedorak, RN 2006Probiotics in the treatment of inflammatory bowel diseaseJ Clin Gastroenterol402603CrossRefPubMed Rioux, KP, Fedorak, RN 2006Probiotics in the treatment of inflammatory bowel diseaseJ Clin Gastroenterol402603CrossRefPubMed
43.
go back to reference Duchmann, R, Schmitt, E, Knolle, P, Meyer zum Buschenfelde, KH, Neurath, M 1996Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12Eur J Immunol269348CrossRefPubMed Duchmann, R, Schmitt, E, Knolle, P, Meyer zum Buschenfelde, KH, Neurath, M 1996Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12Eur J Immunol269348CrossRefPubMed
44.
go back to reference Stadnicki, A, Colman, RW 2003Experimental models of inflammatory bowel diseaseArch Immunol Ther Exp5114955 Stadnicki, A, Colman, RW 2003Experimental models of inflammatory bowel diseaseArch Immunol Ther Exp5114955
45.
go back to reference Arnott, ID, Landers, CJ, Nimmo, EJ, Drummond, HE, Smith, BK, Targan, SR, et al. 2004Sero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/CARD15 genotypeAm J Gastroenterol99237684CrossRefPubMed Arnott, ID, Landers, CJ, Nimmo, EJ, Drummond, HE, Smith, BK, Targan, SR,  et al. 2004Sero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/CARD15 genotypeAm J Gastroenterol99237684CrossRefPubMed
46.
go back to reference Landers, CJ, Cohavy, O, Misra, R, Yang, H, Lin, YC, Braun, J, et al. 2002Selected loss of tolerance evidenced by Crohn’s disease-associated immune responses to auto- and microbial antigensGastroenterology12368999CrossRefPubMed Landers, CJ, Cohavy, O, Misra, R, Yang, H, Lin, YC, Braun, J,  et al. 2002Selected loss of tolerance evidenced by Crohn’s disease-associated immune responses to auto- and microbial antigensGastroenterology12368999CrossRefPubMed
47.
go back to reference Lodes, MJ, Cong, Y, Elson, CO, Mohamath, R, Landers, CJ, Targan, SR, et al. 2004Bacterial flagellin is a dominant antigen in Crohn diseaseJ Clin Invest1131296306PubMed Lodes, MJ, Cong, Y, Elson, CO, Mohamath, R, Landers, CJ, Targan, SR,  et al. 2004Bacterial flagellin is a dominant antigen in Crohn diseaseJ Clin Invest1131296306PubMed
48.
go back to reference Mow, WS, Vasiliauskas, EA, Lin, YC, Fleshner, PR, Papadakis, KA, Taylor, KD, et al. 2004Association of antibody responses to microbial antigens and complications of small bowel Crohn’s diseaseGastroenterology12641424CrossRefPubMed Mow, WS, Vasiliauskas, EA, Lin, YC, Fleshner, PR, Papadakis, KA, Taylor, KD,  et al. 2004Association of antibody responses to microbial antigens and complications of small bowel Crohn’s diseaseGastroenterology12641424CrossRefPubMed
49.
go back to reference Dieleman, LA, Goerres, MS, Arends, A, Sprengers, D, Torrice, C, Hoentjen, F, et al. 2003Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatmentGut523706CrossRefPubMed Dieleman, LA, Goerres, MS, Arends, A, Sprengers, D, Torrice, C, Hoentjen, F,  et al. 2003Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatmentGut523706CrossRefPubMed
50.
go back to reference Kim, SC, Tonkonogy, SL, Albright, CA, Tsang, J, Balish, EJ, Braun, J, et al. 2005Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteriaGastroenterology128891906CrossRefPubMed Kim, SC, Tonkonogy, SL, Albright, CA, Tsang, J, Balish, EJ, Braun, J,  et al. 2005Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteriaGastroenterology128891906CrossRefPubMed
51.
go back to reference Ahmad, T, Satsangi, J, McGovern, D, Bunce, M, Jewell, DP 2001Review article: the genetics of inflammatory bowel diseaseAliment Pharmacol Ther1573148CrossRefPubMed Ahmad, T, Satsangi, J, McGovern, D, Bunce, M, Jewell, DP 2001Review article: the genetics of inflammatory bowel diseaseAliment Pharmacol Ther1573148CrossRefPubMed
52.
go back to reference Hampe, J, Cuthbert, A, Croucher, PJ, Mirza, MM, Mascheretti, S, Fisher, S, et al. 2001Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populationsLancet35719258CrossRefPubMed Hampe, J, Cuthbert, A, Croucher, PJ, Mirza, MM, Mascheretti, S, Fisher, S,  et al. 2001Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populationsLancet35719258CrossRefPubMed
53.
go back to reference Hugot, JP, Chamaillard, M, Zouali, H, Lesage, S, Cezard, JP, Belaiche, J, et al. 2001Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s diseaseNature411599603CrossRefPubMed Hugot, JP, Chamaillard, M, Zouali, H, Lesage, S, Cezard, JP, Belaiche, J,  et al. 2001Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s diseaseNature411599603CrossRefPubMed
54.
go back to reference Ogura, Y, Bonen, DK, Inohara, N, Nicolae, DL, Chen, FF, Ramos, R, et al. 2001A frameshift mutation in NOD2 associated with susceptibility to Crohn’s diseaseNature4116036CrossRefPubMed Ogura, Y, Bonen, DK, Inohara, N, Nicolae, DL, Chen, FF, Ramos, R,  et al. 2001A frameshift mutation in NOD2 associated with susceptibility to Crohn’s diseaseNature4116036CrossRefPubMed
55.
go back to reference Inohara, N, Ogura, Y, Fontalba, A, Gutierrez, O, Pons, F, Crespo, J, et al. 2003Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s diseaseJ Biol Chem278550912CrossRefPubMed Inohara, N, Ogura, Y, Fontalba, A, Gutierrez, O, Pons, F, Crespo, J,  et al. 2003Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s diseaseJ Biol Chem278550912CrossRefPubMed
56.
go back to reference Maeda, S, Hsu, LC, Liu, H, Bankston, LA, Iimura, M, Kagnoff, MF, et al. 2005Nod2 mutation in Crohn’s disease potentiates NF-kappaB activity and IL-1beta processingScience3077348CrossRefPubMed Maeda, S, Hsu, LC, Liu, H, Bankston, LA, Iimura, M, Kagnoff, MF,  et al. 2005Nod2 mutation in Crohn’s disease potentiates NF-kappaB activity and IL-1beta processingScience3077348CrossRefPubMed
57.
go back to reference Girardin, SE, Hugot, JP, Sansonetti, PJ 2003Lessons from Nod2 studies: towards a link between Crohn’s disease and bacterial sensingTrends Immunol246528CrossRefPubMed Girardin, SE, Hugot, JP, Sansonetti, PJ 2003Lessons from Nod2 studies: towards a link between Crohn’s disease and bacterial sensingTrends Immunol246528CrossRefPubMed
58.
go back to reference Watanabe, T, Kitani, A, Murray, PJ, Strober, W 2004NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responsesNat Immunol58008CrossRefPubMed Watanabe, T, Kitani, A, Murray, PJ, Strober, W 2004NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responsesNat Immunol58008CrossRefPubMed
59.
go back to reference Bilsborough, J, Viney, JL 2004Gastrointestinal dendritic cells play a role in immunity, tolerance, and diseaseGastroenterology1273009CrossRefPubMed Bilsborough, J, Viney, JL 2004Gastrointestinal dendritic cells play a role in immunity, tolerance, and diseaseGastroenterology1273009CrossRefPubMed
60.
go back to reference Niess, JH, Brand, S, Gu, X, Landsman, L, Jung, S, McCormick, BA, et al. 2005CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearanceScience3072548CrossRefPubMed Niess, JH, Brand, S, Gu, X, Landsman, L, Jung, S, McCormick, BA,  et al. 2005CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearanceScience3072548CrossRefPubMed
61.
go back to reference Savidge, TC, Newman, PG, Pan, WH, Weng, MQ, Shi, HN, McCormick, BA, et al. 2006Lipopolysaccharide-induced human enterocyte tolerance to cytokine-mediated interleukin-8 production may occur independently of TLR-4/MD-2 signalingPediatr Res598995CrossRefPubMed Savidge, TC, Newman, PG, Pan, WH, Weng, MQ, Shi, HN, McCormick, BA,  et al. 2006Lipopolysaccharide-induced human enterocyte tolerance to cytokine-mediated interleukin-8 production may occur independently of TLR-4/MD-2 signalingPediatr Res598995CrossRefPubMed
62.
go back to reference Tyrer, P, Foxwell, AR, Cripps, AW, Apicella, MA, Kyd, JM 2006Microbial pattern recognition receptors mediate M-cell uptake of a gram-negative bacteriumInfect Immun7462531CrossRefPubMed Tyrer, P, Foxwell, AR, Cripps, AW, Apicella, MA, Kyd, JM 2006Microbial pattern recognition receptors mediate M-cell uptake of a gram-negative bacteriumInfect Immun7462531CrossRefPubMed
63.
go back to reference Korzenik, JR, Dieckgraefe, BK 2000Is Crohn’s disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn’s diseaseDig Dis Sci4511219CrossRefPubMed Korzenik, JR, Dieckgraefe, BK 2000Is Crohn’s disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn’s diseaseDig Dis Sci4511219CrossRefPubMed
64.
go back to reference Korzenik, JR, Dieckgraefe, BK 2005An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn’s diseaseAliment Pharmacol Ther21391400CrossRefPubMed Korzenik, JR, Dieckgraefe, BK 2005An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn’s diseaseAliment Pharmacol Ther21391400CrossRefPubMed
65.
go back to reference Dieckgraefe, BK, Korzenik, JR 2002Treatment of active Crohn’s disease with recombinant human granulocyte-macrophage colony-stimulating factor [see comment]Lancet360147880CrossRefPubMed Dieckgraefe, BK, Korzenik, JR 2002Treatment of active Crohn’s disease with recombinant human granulocyte-macrophage colony-stimulating factor [see comment]Lancet360147880CrossRefPubMed
66.
go back to reference Korzenik, JR, Dieckgraefe, BK, Valentine, JF, Hausman, DF, Gilbert, MJ 2005Sargramostim in Crohn’s Disease Study G. Sargramostim for active Crohn’s diseaseN Engl J Med3522193201CrossRefPubMed Korzenik, JR, Dieckgraefe, BK, Valentine, JF, Hausman, DF, Gilbert, MJ 2005Sargramostim in Crohn’s Disease Study G. Sargramostim for active Crohn’s diseaseN Engl J Med3522193201CrossRefPubMed
67.
go back to reference http://www.schering.de/scripts/en/50_media/2006/pi/Q3/060731_Leukine.php?n=mep accessed on 10 December 2006 http://www.schering.de/scripts/en/50_media/2006/pi/Q3/060731_Leukine.php?n=mep accessed on 10 December 2006
68.
go back to reference Mosmann, TR, Sad, S 1996The expanding universe of T-cell subsets: Th1, Th2 and moreImmunol Today1713846CrossRefPubMed Mosmann, TR, Sad, S 1996The expanding universe of T-cell subsets: Th1, Th2 and moreImmunol Today1713846CrossRefPubMed
69.
go back to reference Fuss, IJ, Neurath, M, Boirivant, M, Klein, JS, Motte, C, Strong, SA, et al. 1996Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5J Immunol157126170PubMed Fuss, IJ, Neurath, M, Boirivant, M, Klein, JS, Motte, C, Strong, SA,  et al. 1996Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5J Immunol157126170PubMed
70.
go back to reference Derkx, B, Taminiau, J, Radema, S, Stronkhorst, A, Wortel, C, Tytgat, G, et al. 1993Tumour-necrosis-factor antibody treatment in Crohn’s diseaseLancet3421734CrossRefPubMed Derkx, B, Taminiau, J, Radema, S, Stronkhorst, A, Wortel, C, Tytgat, G,  et al. 1993Tumour-necrosis-factor antibody treatment in Crohn’s diseaseLancet3421734CrossRefPubMed
71.
go back to reference Dullemen, HM, Deventer, SJ, Hommes, DW, Bijl, HA, Jansen, J, Tytgat, GN, et al. 1995Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology10912935CrossRefPubMed Dullemen, HM, Deventer, SJ, Hommes, DW, Bijl, HA, Jansen, J, Tytgat, GN,  et al. 1995Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology10912935CrossRefPubMed
72.
go back to reference Targan, SR, Hanauer, SB, Deventer, SJ, Mayer, L, Present, DH, Braakman, T, et al. 1997A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study GroupN Engl J Med337102935CrossRefPubMed Targan, SR, Hanauer, SB, Deventer, SJ, Mayer, L, Present, DH, Braakman, T,  et al. 1997A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study GroupN Engl J Med337102935CrossRefPubMed
73.
go back to reference Hanauer, SB, Feagan, BG, Lichtenstein, GR, Mayer, LF, Schreiber, S, Colombel, JF, et al. 2002Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trialLancet35915419CrossRefPubMed Hanauer, SB, Feagan, BG, Lichtenstein, GR, Mayer, LF, Schreiber, S, Colombel, JF,  et al. 2002Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trialLancet35915419CrossRefPubMed
74.
go back to reference Sands, BE, Anderson, FH, Bernstein, CN, Chey, WY, Feagan, BG, Fedorak, RN, et al. 2004Infliximab maintenance therapy for fistulizing Crohn’s diseaseN Engl J Med35087685CrossRefPubMed Sands, BE, Anderson, FH, Bernstein, CN, Chey, WY, Feagan, BG, Fedorak, RN,  et al. 2004Infliximab maintenance therapy for fistulizing Crohn’s diseaseN Engl J Med35087685CrossRefPubMed
75.
go back to reference Hanauer, SB, Sandborn, WJ, Rutgeerts, P, Fedorak, RN, Lukas, M, MacIntosh, D, et al. 2006Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trialGastroenterology13032333quiz 591CrossRefPubMed Hanauer, SB, Sandborn, WJ, Rutgeerts, P, Fedorak, RN, Lukas, M, MacIntosh, D,  et al. 2006Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trialGastroenterology13032333quiz 591CrossRefPubMed
76.
go back to reference Schreiber, S, Rutgeerts, P, Fedorak, RN, Khaliq-Kareemi, M, Kamm, MA, Boivin, M, et al. 2005A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s diseaseGastroenterology12980718CrossRefPubMed Schreiber, S, Rutgeerts, P, Fedorak, RN, Khaliq-Kareemi, M, Kamm, MA, Boivin, M,  et al. 2005A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s diseaseGastroenterology12980718CrossRefPubMed
77.
go back to reference Colombel, JF, Sandborn, WJ, Rutgeerts, P, Enns, R, Hanauer, SB, Panaccione, R, et al. 2006Adalimumab induces and maintains clinical response and remission in patients with active Crohn’s disease: results of the CHARM trialGastroenterology131950CrossRef Colombel, JF, Sandborn, WJ, Rutgeerts, P, Enns, R, Hanauer, SB, Panaccione, R,  et al. 2006Adalimumab induces and maintains clinical response and remission in patients with active Crohn’s disease: results of the CHARM trialGastroenterology131950CrossRef
78.
go back to reference Sandborn, WJ, Feagan, BG, Stoinov, S, Honiball, PJ, Rutgeerts, P, McColm, JA, et al. 2006Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn’s disease: results from a 26-week, placebo-controlled phase iii study (PRECiSE 1)Gastroenterology130A107 Sandborn, WJ, Feagan, BG, Stoinov, S, Honiball, PJ, Rutgeerts, P, McColm, JA,  et al. 2006Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn’s disease: results from a 26-week, placebo-controlled phase iii study (PRECiSE 1)Gastroenterology130A107
79.
go back to reference Siegel, CA, Hur, C, Korzenik, JR, Gazelle, GS, Sands, BE 2006Risks and benefits of infliximab for the treatment of Crohn’s diseaseClin Gastroenterol Hepatol4101724quiz 976CrossRefPubMed Siegel, CA, Hur, C, Korzenik, JR, Gazelle, GS, Sands, BE 2006Risks and benefits of infliximab for the treatment of Crohn’s diseaseClin Gastroenterol Hepatol4101724quiz 976CrossRefPubMed
80.
go back to reference Colombel, JF, Loftus, EV,Jr, Tremaine, WJ, Egan, LJ, Harmsen, WS, Schleck, CD, et al. 2004The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patientsGastroenterology1261931CrossRefPubMed Colombel, JF, Loftus, EV,Jr, Tremaine, WJ, Egan, LJ, Harmsen, WS, Schleck, CD,  et al. 2004The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patientsGastroenterology1261931CrossRefPubMed
81.
go back to reference Schreiber, S, Fedorak, RN, Nielsen, OH, Wild, G, Williams, CN, Nikolaus, S, et al. 2000Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Crohn’s Disease IL-10 Cooperative Study GroupGastroenterology119146172CrossRefPubMed Schreiber, S, Fedorak, RN, Nielsen, OH, Wild, G, Williams, CN, Nikolaus, S,  et al. 2000Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Crohn’s Disease IL-10 Cooperative Study GroupGastroenterology119146172CrossRefPubMed
82.
go back to reference Assche, G, Sandborn, WJ, Feagan, BG, Salzberg, BA, Silvers, D, Monroe, PS, et al. 2006Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trialGut55156874CrossRefPubMed Assche, G, Sandborn, WJ, Feagan, BG, Salzberg, BA, Silvers, D, Monroe, PS,  et al. 2006Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trialGut55156874CrossRefPubMed
83.
go back to reference Mannon, PJ, Fuss, IJ, Mayer, L, Elson, CO, Sandborn, WJ, Present, D, et al. 2004Anti-interleukin-12 antibody for active Crohn’s diseaseN Engl J Med351206979CrossRefPubMed Mannon, PJ, Fuss, IJ, Mayer, L, Elson, CO, Sandborn, WJ, Present, D,  et al. 2004Anti-interleukin-12 antibody for active Crohn’s diseaseN Engl J Med351206979CrossRefPubMed
84.
go back to reference Duerr, RH, Taylor, KD, Brant, SR, Rioux, JD, Silverberg, MS, Daly, MJ, et al. 2006A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease GeneScience31414613CrossRefPubMed Duerr, RH, Taylor, KD, Brant, SR, Rioux, JD, Silverberg, MS, Daly, MJ,  et al. 2006A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease GeneScience31414613CrossRefPubMed
85.
go back to reference Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-4 Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-4
86.
go back to reference Berlin, C, Berg, EL, Briskin, MJ, Andrew, DP, Kilshaw, PJ, Holzmann, B, et al. 1993Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1Cell7418595CrossRefPubMed Berlin, C, Berg, EL, Briskin, MJ, Andrew, DP, Kilshaw, PJ, Holzmann, B,  et al. 1993Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1Cell7418595CrossRefPubMed
87.
go back to reference Ghosh, S, Goldin, E, Gordon, FH, Malchow, HA, Rask-Madsen, J, Rutgeerts, P, et al. 2003Natalizumab for active Crohn’s diseaseN Engl J Med3482432CrossRefPubMed Ghosh, S, Goldin, E, Gordon, FH, Malchow, HA, Rask-Madsen, J, Rutgeerts, P,  et al. 2003Natalizumab for active Crohn’s diseaseN Engl J Med3482432CrossRefPubMed
88.
go back to reference Sandborn, WJ, Colombel, JF, Enns, R, Feagan, BG, Hanauer, SB, Lawrance, IC, et al. 2005Natalizumab induction and maintenance therapy for Crohn’s diseaseN Engl J Med353191225CrossRefPubMed Sandborn, WJ, Colombel, JF, Enns, R, Feagan, BG, Hanauer, SB, Lawrance, IC,  et al. 2005Natalizumab induction and maintenance therapy for Crohn’s diseaseN Engl J Med353191225CrossRefPubMed
89.
go back to reference Targan, S, Feagan, B, Fedorak, R, Lashner, B, Panacionne, R, Present, D, et al. 2006Natalizumab induces sustained response and remission in patients with active Crohn’s disease: results from the Encore trialGastroenterology130A108 Targan, S, Feagan, B, Fedorak, R, Lashner, B, Panacionne, R, Present, D,  et al. 2006Natalizumab induces sustained response and remission in patients with active Crohn’s disease: results from the Encore trialGastroenterology130A108
90.
go back to reference Assche, G, Van Ranst, M, Sciot, R, Dubois, B, Vermeire, S, Noman, M, et al. 2005Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s diseaseN Engl J Med3533628CrossRefPubMed Assche, G, Van Ranst, M, Sciot, R, Dubois, B, Vermeire, S, Noman, M,  et al. 2005Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s diseaseN Engl J Med3533628CrossRefPubMed
91.
go back to reference Feagan, BG, Greenberg, GR, Wild, G, Fedorak, RN, Pare, P, McDonald, JW, et al. 2005Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrinN Engl J Med3522499507CrossRefPubMed Feagan, BG, Greenberg, GR, Wild, G, Fedorak, RN, Pare, P, McDonald, JW,  et al. 2005Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrinN Engl J Med3522499507CrossRefPubMed
92.
94.
go back to reference Seder, RA, Germain, RN, Linsley, PS, Paul, WE 1994CD28-mediated costimulation of interleukin 2 (IL-2) production plays a critical role in T cell priming for IL-4 and interferon gamma productionJ Exp Med179299304CrossRefPubMed Seder, RA, Germain, RN, Linsley, PS, Paul, WE 1994CD28-mediated costimulation of interleukin 2 (IL-2) production plays a critical role in T cell priming for IL-4 and interferon gamma productionJ Exp Med179299304CrossRefPubMed
95.
go back to reference Katz, S 2005Update in medical therapy of ulcerative colitis: newer concepts and therapies [erratum appears in J Clin Gastroenterol 2005;39:843]J Clin Gastroenterol3955769CrossRefPubMed Katz, S 2005Update in medical therapy of ulcerative colitis: newer concepts and therapies [erratum appears in J Clin Gastroenterol 2005;39:843]J Clin Gastroenterol3955769CrossRefPubMed
96.
go back to reference Genovese, MC, Becker, JC, Schiff, M, Luggen, M, Sherrer, Y, Kremer, J, et al. 2005Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibitionN Engl J Med353111423CrossRefPubMed Genovese, MC, Becker, JC, Schiff, M, Luggen, M, Sherrer, Y, Kremer, J,  et al. 2005Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibitionN Engl J Med353111423CrossRefPubMed
97.
go back to reference Groux, H, O’Garra, A, Bigler, M, Rouleau, M, Antonenko, S, de Vries, JE, et al. 1997A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitisNature38973742CrossRefPubMed Groux, H, O’Garra, A, Bigler, M, Rouleau, M, Antonenko, S, de Vries, JE,  et al. 1997A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitisNature38973742CrossRefPubMed
98.
go back to reference Weiner, HL 2001Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cellsImmunol Rev18220714CrossRefPubMed Weiner, HL 2001Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cellsImmunol Rev18220714CrossRefPubMed
99.
go back to reference Dieckmann, D, Bruett, CH, Ploettner, H, Lutz, MB, Schuler, G 2002Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cellsJ Exp Med19624753CrossRefPubMed Dieckmann, D, Bruett, CH, Ploettner, H, Lutz, MB, Schuler, G 2002Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cellsJ Exp Med19624753CrossRefPubMed
100.
go back to reference Montfrans, C, Hooijberg, E, Rodriguez Pena, MS, Jong, EC, Spits, H, Te Velde, AA, et al. 2002Generation of regulatory gut-homing human T lymphocytes using ex vivo interleukin 10 gene transferGastroenterology123187788CrossRefPubMed Montfrans, C, Hooijberg, E, Rodriguez Pena, MS, Jong, EC, Spits, H, Te Velde, AA,  et al. 2002Generation of regulatory gut-homing human T lymphocytes using ex vivo interleukin 10 gene transferGastroenterology123187788CrossRefPubMed
101.
go back to reference Hurles M. Are 100000 “SNPs” useless? Science 2002;298:1509; author reply 1509 Hurles M. Are 100000 “SNPs” useless? Science 2002;298:1509; author reply 1509
Metadata
Title
Inflammatory bowel disease: past, present, and future
Author
Bruce E. Sands
Publication date
01-01-2007
Publisher
Springer-Verlag
Published in
Journal of Gastroenterology / Issue 1/2007
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-006-1995-7

Other articles of this Issue 1/2007

Journal of Gastroenterology 1/2007 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.